Synthetic withdraws 'breakthrough' designation on data review

Synthetic Biologics Inc. (NYSE-A:SYN) said it withdrew the breakthrough therapy designation granted by FDA to ribaxamase (SYN-004) to prevent Clostridium difficile infection (CDI) after the agency

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE